Printer Friendly

ALAMAR BIOSCIENCES REPORTS FIRST QUARTER EARNINGS

 SACRAMENTO, Calif., Jan. 21 /PRNewswire/ -- Alamar Biosciences Inc. (NASDAQ: ALMRU) a research and development company specializing in the development, manufacturing and marketing of in vitro (outside the body) diagnostic testing products, today reported financial results for the first quarter ended Dec. 31, 1992.
 For the first quarter, sales sharply increased to $46,500, compared to $3,640 for the first quarter in 1991. During the quarter, gross profits were $23,690, compared to a loss of $2,590 for the quarter in 1991. Alamar reported a net loss for the first quarter of $774,550, or 28 cents per share, compared to a net loss of $751,050, or 34 cents per share, in the prior-year period. Research and development expenses were down 6 percent to $428,900 for the quarter.
 Alamar's chief executive officer, Kenneth D. Miller, said "The sharp increase in our sales performance is attributable to revenue earned for progress made under our development pact with Pfizer, sales of alamar Blue(TM) and increased sales of our diagnostic test kits and supplies."
 Alamar is developing an in vitro antifungal susceptibility test kit under a development pact with the Roerig division of Pfizer Inc. The kit will determine medication type and dosage effective in treating yeast infections. Alamar receives payments for work progress and retains the exclusive right to any product developed under the agreement.
 "During the first quarter, we continued to focus on developing our sales and marketing force and obtaining Food and Drug Administration approval on other products that will make up our product portfolio," Miller said. Alamar expects FDA approval of its in vitro bacterial identification test kit and its READar semi-automated test reading instrument in early 1993, which will give the company a complete portfolio of products addressing three-fourths of the $530 million worldwide bacterial identification and susceptibility market.
 At Dec. 31, 1992, total assets were $3,823,600, significantly up from $1,702,600 in 1991. Shareholders' equity was $3,412,400, a 126-percent increase over the first quarter 1991 figure of $1,509,200. There were 2,802,860 weighted average common shares outstanding for the quarter.
 Formed in 1988, Alamar Biosciences Inc. is traded on NASDAQ under the symbol ALMRU. The company develops, manufactures and markets in vitro disposable testing products for hospitals, reference laboratories and other health care providers. Alamar currently markets bacterial identification and antibiotic dosage effectiveness test kits and alamar Blue(TM), an indicator dye for determining cell viability in research and biotechnology applications.
 -0- 1/21/93
 /CONTACT: Kenneth Miller, chief executive officer of Alamar Biosciences 916-567-3475; Elizabeth Truax, 415-986-1591 or Kathy Brunson, 312-266-7800, both of The Financial Relations Board/
 (ALMRU)


CO: Alamar Biosciences Inc. ST: California IN: MTC SU: ERN

RK-SG -- SF002 -- 7249 01/21/93 09:03 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 21, 1993
Words:463
Previous Article:LUKENS NAMES NEW CORPORATE EXECUTIVES: T. GRANT JOHN -- VP OF PLANNING/STAINLESS STEEL, RICHARD D. LUZZI -- VP OF HUMAN RESOURCES
Next Article:WEITEK PROCESSOR TAKES DESIGN WIN FOR CANON LBP-8 MARK IV PRINTER; NEW GENERATION OF 600-DPI PRODUCTS TO BE POWERED BY WEITEK XL-8220
Topics:


Related Articles
ALAMAR BIOSCIENCES REPORTS YEAR-END RESULTS
ALAMAR BIOSCIENCES REPORTS SECOND QUARTER RESULTS
ALAMAR BIOSCIENCES RAISES OVER $3.1 MILLION THROUGH PRIVATE FINANCINGS
ALAMAR BIOSCIENCES REPORTS FISCAL 1993 RESULTS
ALAMAR BIOSCIENCES REPORTS SECOND QUARTER RESULTS; REVENUES INCREASE NEARLY FIVE-FOLD
ALAMAR ANNOUNCES DIFCO AGREEMENT
ALAMAR BIOSCIENCES REPORTS FISCAL 1994 RESULTS
AccuMed International Achieves Record Results for the Third Quarter Ended September 30, 1996
AccuMed International Reports Fourth-Quarter and Year-End Results
CN Biosciences, Inc. Reports Second Quarter 1997 Financial Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters